share_log

Avenue Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Fortress Biotech, Inc.

SEC announcement ·  Apr 17 16:10
Summary by Moomoo AI
Fortress Biotech, Inc., reported a completed transaction involving the acquisition of 413,507 shares of common stock in Avenue Therapeutics, Inc. (ATXI) on April 16, 2024. The shares were granted at no cost, as indicated by a transaction price of $0.00. Following this transaction, Fortress Biotech's direct holdings in Avenue Therapeutics increased to a total of 3,547,393 shares. The nature of the transaction was described as a grant, award, or other acquisition, according to the transaction code 'A'. This event reflects a significant increase in Fortress Biotech's stake in the pharmaceutical company.
Fortress Biotech, Inc., reported a completed transaction involving the acquisition of 413,507 shares of common stock in Avenue Therapeutics, Inc. (ATXI) on April 16, 2024. The shares were granted at no cost, as indicated by a transaction price of $0.00. Following this transaction, Fortress Biotech's direct holdings in Avenue Therapeutics increased to a total of 3,547,393 shares. The nature of the transaction was described as a grant, award, or other acquisition, according to the transaction code 'A'. This event reflects a significant increase in Fortress Biotech's stake in the pharmaceutical company.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more